The efficacy of low dose long-term erythromycin (EM) therapy in the treatment of chronic lower respiratory tract disease, including diffuse panbronchiolitis (DPB), has been reported, but its therapeutic mechanism is still unclear. In 13 patients receiving oral EM therapy the accumulation of neutrophils in bronchoalveolar lavage (BAL) fluid was significantly reduced (p<0.05), this reduction corresponds with an improvement in clinical symptoms. We sought to determine whether neutrophil chemotactic activity (NCA) in lavage fluid obtained from these 13 patients with DPB would respond to EM therapy. Pretreatment NCA in all patients was significantly elevated compared with levels in normal healthy nonsmoking volunteers (p<0.001), and the level was greatly reduced after EM therapy (p<0.001). In addition, this reduction correlated with increased percentages of neutrophils in the BAL fluid (r=0.737, p<0.01). Gel-filtration chromatography was also performed to characterize chemotactic factors. Pre-EM treatment BAL fluid revealed four NCA peaks (about molecular weight 15,000, 8,000, 1,500, and 300 daltons) in the elution pro1iffuse panbronchiolitis (DPB), an important pulmonary disease entity, was first reported in 1969 in Japan as an entity distinct from bronchial asthma, chronic bronchitis, chronic pulmonary emphysema, bronchiectasis, and alveolitis. This disease is characterized by chronic inflammation localized predominantly in the region of the respiratory bronchioles with inflammatory cell infiltration;'-3 its pathogenesis remains unknown. Although not uncommon in Japan, the disease is rare elsewhere. There have been recent reports, however, documented of two cases in white North American patients4 and of the first case in an Italian patient. 5 The chief signs of this disease are chronic cough, pyomucous sputum, shortness of breath, wheezing, and hypoxemia. About threequarters of these patients have associated chronic parasinusitis. Chest roentgenograms show bilateral fine nodular densities, together with hyperinflation of both lungs. Pulmonary function tests show a mixed ventilatory impairment consisting of slight restrictive and marked obstructive disturbance. The HLABw54, found specifically in Japanese and Chinese people, is found more frequently in DPB cases than in healthy persons. Associated diseases include ulcerative colitis, allergic angitis and granulomatosis, and T cell leukemia. [6] [7] [8] Reports Diffuse panbronchiolitis progresses insidiously and the prognosis, especially after Pseudomonas aeruginosa superinfection, is generally poor. Recently, low dose long-term erythromycin (EM) treatment has become the preferred therapy for chronic lower respiratory tract disease, including DPB." That erythromycin may act as an anti-inflammatory agent is indicated by recent reports that it raises natural killer cell activity12 and has potent capacity to suppress the polymorphonuclear leukocyte (PMN) chemiluminescence induced by N-formyl-methionyl-leucylphenylalanine (FMLP), opsonized zymosan, and the calcium ionophore, A23187.13 The mechanism responsible for the therapeutic action of EM, however, is still unclear. Our recent finding indicated marked neutrophil accumulation in the lung of patients with DPB.14 Accordingly, in an attempt to elucidate this mechanism, we investigated the effect of EM on neutrophil migration, and we attempted to characterize the neutrophil chemotactic factors in the bronchoalveolar lavage (BAL) fluid of patients with DPB.
MATERIALS AND METHODS

Patient Population
We evaluated neutrophil chemotactic activity (NCA) in 13 patients with DPB (10 men and 3 women; mean age 39.2+4.9 years) who satisfied the diagnostic criteria for DPB set out by the Japanese Ministry of Health and Welfare. All the patients had the following clinical features: (1) symptoms of chronic cough with sputum production and exertional dyspnea, (2) physical signs of coarse crackles and rhonchi, (3) typical radiologic features on chest roentgenogram of diffuse nodular shadows and hyperinflation, (4) chronic paranasal sinusitis, and (5) pulmonary function tests showing ventilatory defects that were obstructive, or rarely restrictive, and hypoxemia with or without hypercapnia. In 9 of the 13 patients the disease was histologically confirmed in open lung biopsies; in the remaining four patients, it was diagnosed clinically. All the patients were nonsmokers. When patients had signs or roentgenographic findings suggesting pneumonia or acute exacerbation of the disease before enrollment in the study, adequate antibiotics were administered. Thus, none of the patients had a pulmonary infection in the 1 month before enrollment in the study. For comparison, five healthy nonsmoking volunteers also were evaluated.
Erythromycin Treatment
All patients received 200 mg of erythromycin stearate orally 3 times per day for more than 6 months until BAL was repeated. The patients were instructed at each outpatient attendance to take one tablet every 8 hours, at home, and they were given a 4-week supply. They were instructed to bring back any remaining tablets at each visit to that the numbers of remaining tablets could be checked. None of the patients received corticosteroids or antibiotics other than EM for the duration of this study.
Bronchoalveolar Lavage
The patients were premedicated intramuscularly with atropine (0.5 mg) and local anesthesia was produced with 2 percent lidocaine; airway examination was then carri-d out with a flexible fiberoptic bronchoscope (Olympas BF-P20 type; Olympus Corp, New Hyde Park, NY).
The bronchoscope was wedged securely into the subsegmental bronchus of the right middle lobe and 150 ml of sterile 0.9 percent NaCl at 37°C was infused in three 50-ml aliquots, and gently aspirated immediately after each infusion. The recovered lavage fluid was pooled, passed through a double layer of gauze to remove gross mucus, then centrifuged. A differential cell count was performed on the pellet, and the supernatant was frozen at -80 0C until used.
Isolation of Human Peripheral Blood Neutrophils
Neutrophils for the chemotactic assay were isolated from a normal healthy volunteer by mono-poly resolving medium (M-PRM; Flow Laboratories, Irvine, Scotland) density gradient centrifugation.'5 The neutrophils were suspended, at a density of 3X106 cells per ml, in Hanks' solution (HBSS, Gibco), pH 7.2, containing 0.1 percent bovine serum albumin (BSA). More than 98 percent of the cells were neutrophils; cell viability was in excess of 95 percent, as determined by trypan blue exclusion.
Neutrophil Chemotaxis Assay
Neutrophil chemotactic activity was assessed using a 48-well microchemotaxis chamber (Neuroprobe Inc, Bethesda, Md) as Gel-filtration Gel-filtration chromatography was performed on a 75 column (1.6-cm diameter, 60-cm long, Superdex, Pharmacia). One-milliliter aliquots of a ten-fold concentrated BAL fluid (freeze-dried 10-ml aliquots solubilized in 1 ml of distilled water) were applied to a column (Superdex) previously equilibrated with phosphate buffered saline (PBS, pH 7.2; Gibco). Chromatography was performed at 40C, with a flow rate of 1.0 ml/min; 5 ml of each fraction was collected. The column was calibrated with molecular weight markers (blue dextran, cytochrome c, insulin, and phenol red). For fractionations, 1.5 mg of protein was used.
Statistical Analysis
All data were expressed as the means ± standard error of the CHEST! 106 / 4 / OCTOBER, 1994 1117 
RESULTS
Clinical Characteristics of Patients
Neutrophil chemotactic activity was measured in the pre-and post-EM treatment BAL fluid of the 13 DPB patients. As shown in Table 1 , their mean duration of disease was 9.0 ± 1.9 years; the onset was insidious. Sputum cultures at the time of admission yielded Hemophilus influenzae in four patients (cases 6, 8, 10, and 11), Pseudomonas aeruginosa in three (cases 4, 9, and 13), Staphylococcus aureus in one (case 1), and normal flora in 5 (cases 2, 3, 5, 7, and 12). Erythromycin was administered to the patients for 9.3 ± 0.8 months. After the treatment, H influenzae was eradicated in three patients but replaced by P aeruginosa in one case. In all 3 patients originally exhibiting P aeruginosa in cultures, the organism was eradicated. In the one patient (case 1) with S aureus, this organism was eradicated, but replaced by H influenzae. In one of the patients with normal flora, these were replaced by H influenzae; in the other such patient, these flora were replaced by P aeruginosa. The bacteria eradication rate was 75.0 percent (6/8 The mean values for BAL parameters before and after EM therapy are shown in Table 3 . The mean values for total cell number and neutrophil percentage before EM treatment were significantly higher than values in healthy volunteers; the values were significantly reduced after EM therapy (p<0.05), corresponding with an improvement in clinical symptoms and findings. Changes in the recovery rate preand post-EM treatment were not significant (48.3 ± 4.3 vs 46.5 ± 5.9 percent). Changes in Neutrophil Chemotactic Activity in BAL Fluid Figure 1 shows the changes in NCA pre-and post-EM treatment in the BAL fluid of patients with DPB. The mean NCA value before EM treatment was 52.9 ± 2.9 percent; and there was a marked reduction in this value after the treatment (30.8 ± 2.5 percent, p<0.001). There were no significant differences between values for albumin concentration in initial BAL fluid samples and in repeated samples (41.8 ± 10.8 vs 39.3 ± 6.8 mg/dl, p=0.85). Additionally, there were no significant correlations between the recovery rate and NCA either in initial BAL fluid samples (r=0.017, p>0.6) or in repeated samples (r= -0.316, p>0.6). Albumin concentration and NCA did not correlate in either the initial or the repeated samples of BAL fluid (initial samples: r=0.102, p>0.6; repeated samples: r=0.254, p>0.6). Thus, we regarded NCA as being unaffected by recovery rate or by albumin concentration, and we, therefore, expressed without correction. Although BAL fluid samples from DPB patients may contain more bacterial endotoxin than samples from healthy subjects, we believe it to be that the endotoxin would not have affected the chemotaxis findings, both in the light of report by Issekutz and Bhimji'7 that endotoxin did not induce neutrophil chemotaxis in the in vitro assay and in the light of our observation here that neither of the two endotoxin preparations (P aeruginosa serotype 10 and Salmonella typhosa; Sigma) tested induced neutrophil chemotaxis in the in vitro assay at concentrations 10 to 100 times higher than those inducing leukocyte infiltration in vivo (data not shown). Analysis of pre-EM treatment BAL fluid obtained from one patient with DPB (case 4) resulted in four peaks of activity; these were estimated to be 15,000, 8,000, 1,500, and 300 daltons (Fig 3) . All four peaks of chemotactic activity in the BAL fluid from this patient were reduced after EM treatment (Fig 4) Fraction number 37 In our present study, we found that treatment with EM significantly reduced the number of intrapulmonary neutrophils, indicating that, in DPB, EM might act first by reducing neutrophil migration and then by inhibiting inappropriate and excessive inflammation in the lower respiratory tract.
The accumulation of neutrophils is induced by a number of chemotactic mediators, including C5a, IL-1, TNFa, IL-8, granulocyte-CSF, granulocytemacrophage-CSF, 5,12-dihydroxyeicosa-tetraenoic acid (LTB4), and endotoxin. [38] [39] [40] [41] [42] [43] [44] [45] We evaluated NCA in pre-and post-EM treatment lavage fluid from DPB patients and found that in post-EM BAL fluid, NCA was significantly reduced, and, interestingly, that this correlated with improvements in neutrophil percentages. In a recent study, Hirata et al13 found that EM had potently suppressed neutrophil chemiluminescence (CL) induced by FMLP stimulation. In contrast, phorbol myristate acetate-induced CL was much less affected. Phorbol myristate acetate activates neutrophils, probably through the activation of protein kinase C. 46 Although the concentration of EM in serum was below the MIC for several pathogenic bacteria, EM was 10-to 25-fold concentrated in neutrophils and alveolar macrophages.47 All these results indicate that EM acts on the intracellular signal pathway, reduces chemotactic activity directly or indirectly, and plays a crucial role in modulating inflammation in the lungs of patients with DPB, all of the effects from EM are from its action in suppressing the oxidative and proteolytic products of neutrophils.
Our chromatographic data showed that the weight after molecular sieving of three of the fractions closely corresponded to the molecular weights of C5a,39 interleukin-8,41 and a lipid-containing substance,42'48 this being a lipoxygenase pathway metabolite of arachidonic acid. All chemotactic factors were reduced after EM treatment, suggesting that these factors are important in neutrophil recruitment. Which of these factors, however, is quantitatively the most important in this regard was not determined from our findings in this study. Nevertheless, it is likely that EM prevents airway damage in this disorder by suppressing neutrophil accumulation, as a consequence of reducing NCA in the inflammatory sites in the lung.
